Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report, Cancer, vol.42, issue.3, pp.531-533, 1988. ,
DOI : 10.1002/1097-0142(19880801)62:3<531::AID-CNCR2820620315>3.0.CO;2-B
Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast Cancer, Seminars in Thrombosis and Hemostasis, vol.17, issue.03, pp.303-312, 1991. ,
DOI : 10.1055/s-2007-1002624
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer, Breast Cancer Research and Treatment, vol.235, issue.3, pp.195-208, 1993. ,
DOI : 10.1007/BF01833260
Invasion marker PAI???1 remains a strong prognostic factor after long???term follow???up both for primary breast cancer and following first relapse, Breast Cancer Research and Treatment, vol.83, issue.2, pp.147-157, 1999. ,
DOI : 10.1023/A:1006118828278
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients, Cancer Res, vol.60, pp.636-643, 2000. ,
Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients, British Journal of Cancer, vol.88, issue.1, pp.102-108, 2003. ,
DOI : 10.1038/sj.bjc.6600662
Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients, JNCI Journal of the National Cancer Institute, vol.94, issue.2, pp.116-128, 2002. ,
DOI : 10.1093/jnci/94.2.116
Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1, JNCI Journal of the National Cancer Institute, vol.93, issue.12, pp.913-920, 2001. ,
DOI : 10.1093/jnci/93.12.913
Clinical Relevance of Invasion Factors Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 for Individualized Therapy Decisions in Primary Breast Cancer Is Greatest When Used in Combination, Journal of Clinical Oncology, vol.20, issue.4, pp.1000-1007, 2002. ,
DOI : 10.1200/JCO.2002.20.4.1000
Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424), Cancer Res, vol.62, pp.4617-4622, 2002. ,
Predictive Impact of Urokinase-Type Plasminogen Activator: Plasminogen Activator Inhibitor Type-1 Complex on the Efficacy of Adjuvant Systemic Therapy in Primary Breast Cancer, Cancer Research, vol.64, issue.2, pp.659-664, 2004. ,
DOI : 10.1158/0008-5472.CAN-03-1820
Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients, Prospects in diagnosis and treatment, pp.207-218 ,
Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer, The International Journal of Biological Markers, vol.18, issue.2, pp.106-115, 2003. ,
DOI : 10.5301/JBM.2008.666
Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1: Predictors of Poor Response to Tamoxifen Therapy in Recurrent Breast Cancer, JNCI Journal of the National Cancer Institute, vol.87, issue.10, pp.751-756, 1995. ,
DOI : 10.1093/jnci/87.10.751
Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 Workshop, European Journal of Cancer, vol.32, issue.8, pp.1371-1381, 1996. ,
DOI : 10.1016/0959-8049(96)00118-9
Nonparametric Estimation from Incomplete Observations, Journal of the American Statistical Association, vol.37, issue.282, pp.457-481, 1958. ,
DOI : 10.1214/aoms/1177731566
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples, British Journal of Cancer, vol.35, issue.1, pp.1-39, 1977. ,
DOI : 10.1038/bjc.1977.1
Regression Models and Life-Tables, J R Stat Soc, vol.34, pp.187-220, 1972. ,
DOI : 10.1007/978-1-4612-4380-9_37
Multiparametric duplex real-time nucleic acid sequence-based amplification assay for mRNA profiling, Biotechniques, vol.37, pp.476-481, 2004. ,
Urokinase-Type Plasminogen Activator and Its Inhibitor Type 1 Predict Disease Outcome and Therapy Response in Primary Breast Cancer, Clinical Breast Cancer, vol.5, issue.5, pp.348-352, 2004. ,
DOI : 10.3816/CBC.2004.n.040
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer, Thrombosis and Haemostasis, vol.91, pp.450-456, 2004. ,
DOI : 10.1160/TH03-12-0798
External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts, British Journal of Cancer, vol.78, issue.11, pp.1434-1441, 1998. ,
DOI : 10.1038/bjc.1998.704
Urokinasetype plasminogen activator system and breast cancer (Review), Oncology Reports, vol.14, pp.105-112, 2005. ,
Cellular localisation byin situ hybridisation of cathepsin D, stromelysin 3, and urokinase plasminogen activator RNAs in breast cancer, Breast Cancer Research and Treatment, vol.45, issue.2, pp.217-226, 1996. ,
DOI : 10.1007/BF01806676
Inverse Correlation between mRNA Expression of Plasminogen Activator Inhibitor-2 and Lymph Node Metastasis in Human Breast Cancer, Japanese Journal of Cancer Research, vol.311, issue.Suppl., pp.480-487, 1996. ,
DOI : 10.1111/j.1349-7006.1996.tb00249.x
Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues, The Journal of Pathology, vol.53, issue.4, pp.388-397, 1997. ,
DOI : 10.1002/(SICI)1096-9896(199712)183:4<388::AID-PATH943>3.0.CO;2-I
Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer, Clin Cancer Res, vol.5, pp.1497-1502, 1999. ,
Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases -a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases, Breast Cancer Research and Treatment, vol.61, issue.1, pp.1-12, 2000. ,
DOI : 10.1023/A:1006445129195
Expression of a novel factor, com1, in early tumor progression of breast cancer, Clin Cancer Res, vol.6, pp.1778-1783, 2000. ,
Quantitative real-time reverse transcription- PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer, Clin Chem, vol.48, pp.1288-1295, 2002. ,
Prognostic significance of the combined expression of matrix metalloproteinase-9, urokinase type plasminogen activator and its receptor in breast cancer as measured by Northern blot analysis, Int J Biol Markers, vol.16, pp.62-68, 2001. ,
Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer, Anticancer Res, vol.22, pp.2997-3003, 2002. ,
Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients, Clin Cancer Res, vol.3, pp.233-239, 1997. ,
Plasminogen Activator Inhibitor-1 as a Potential Marker for the Malignancy of Esophageal Squamous Cell Carcinoma, Clinical Cancer Research, vol.10, issue.4, pp.1375-1378, 2004. ,
DOI : 10.1158/1078-0432.CCR-03-0196
Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer, British Journal of Cancer, vol.8, issue.7, pp.799-803, 2005. ,
DOI : 10.1186/1471-244X-3-5
XR a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro, Anticancer Drugs, vol.5967, issue.1, pp.37-44 ,